A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis
E. Heathcote. Abstract 479.
 

Descargar archivo

Final Analysis of Virological Outcomes and Resistance During 5 Years of Adefovir Dipivoxil Monotherapy in HBeAg- Negative Patients
K. Borroto-Esoda. Abstract 477.

Descargar archivo

Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine- Resistant Chronic Hepatitis B undergoing Liver Transplantation
E. Schiff. Abstract 480.

Descargar archivo

Durability of HBeAg Seroconversion Following Adefovir Dipivoxil Treatment for Chronic Hepatitis B
T. Chang and others.

Descargar archivo

Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral Therapy in HBeAg- Negative Patients
Y. Murata. Abstract 481.

Entecavir is Associated with an Improvement in Liver Histology and a Reduction in HBV DNA in Patients with Lamivudine-Refractory HBeAg(+) Regardless of Baseline Characteristics
M.L. Shiffman and others
 

Descargar archivo

Continued Virologic and Biochemical Improvement Through 96 Weeks of Entecavir Treatment in HBeAg(-) Chronic Hepatitis B Patients (Study ETV-027)
F. Poordad and others

Descargar archivo

Modeling Clinical Benefits of Suppressing Viral Replication in HBeAg (-) Chronic Hepatitis B Patients: A Number-Needed-to-Treat Analysis of Entecavir and Adefovir
U. Iloeje and others

Descargar archivo

Predicting Liver Disease Complications (HCC and Cirrhosis) in Patients with Chronic Hepatitis B Infection: The R.E.V.E.A.L.- HBV Study
Chen and others

Descargar archivo

Cost-effectiveness of Antivirals in HBeAg-positive Chronic Hepatitis B:Impact of Seroconversion and Viral Suppression
D. Veenstra and others

Descargar archivo